Point-of-Care™ 101

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

Meeting Slides

Clinical Practice Guidelines

Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.

Coleman E, Bockting W, Botzer M, et al. 7th ed. East Dundee, Illinois: World Professional Association for Transgender Health; 2012.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, et al. JAMA. 2018;320(4):379-396.

ASHP [American Society of Health-System Pharmacists] guidelines on pharmacist involvement in HIV care.

Schafer JJ, Gill TK, Sherman EM, et al. Am J Health Syst Pharm. 2016;73(7):468-494.

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.

US Department of Health and Human Services.

Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.

World Health Organization, 2017.

HIV testing guidelines.

Centers for Disease Control and Prevention (CDC), 2020.

Clinical Resources

NAM aidsmap.

Food requirements for anti-HIV medications. Jones A. 2019.


Emory University Rollins School of Public Health, Gilead Sciences, Inc., and the Center for AIDS Research at Emory University (CFAR), 2018.

Database of Antiretroviral Drug Interactions.

HIV InSite. University of California, San Francisco, 2019.

Harm Reduction Coalition.

HIV Testing in Retail Pharmacies (training for pharmacists and pharmacy staff).

Centers for Disease Control and Prevention (CDC), 2020.

Patient and Caregiver Resources

aidsmap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV resources

National Institutes of Health

UCSF Transgender Care

University of California, San Francisco

Suggested Readings

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

Boyd MA, Boffito M, Castagna A, Estrada V. HIV Med. 2019;20(suppl 1):3-11.

Pharmacist-driven rapid ART reduces time to virologic suppression in Rhode Island.

Brotherton AL, Shah RB, Garland J, et al. 27th Conference on Retroviruses and Opportunistic Infections (CROI) 2020; March 8-11, 2020; Boston, MA. Abstract 498.

RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.

Coffey S, Bacchetti P, Sachdev D, et al. AIDS. 2019;33(5):825-832.

A rapid entry program in the South: improving access to care and time to viral suppression.

Colasanti J, Sumitani J, Mehta CC, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI) 2018; March 4−7, 2018; Boston, MA. Abstract 1109.

Assessing the Efficacy and Feasibility of a Retail Pharmacy-Based HIV Testing Program.

Collins BC, Bronson HW, Martin EG. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018;5(7):e347-e356.

HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.

Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019;170:104543.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A. et al. AIDS. 2018;32:17-23.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, et al. Lancet HIV. 2016;3(4):e158-e165.

Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 week results of the NEAT022 study.

Gatell JM, Assoumou L, Moyle G, et al. Clin Infect Dis. 2019;68(4):597-606.

Determination of optimized multidisciplinary care team for maximal antiretrovial therapy adherence.

Horberg MA, Hurley LB, Towner WJ, et al. J Acquir Immune Defic Syndr. 2012; 60(2):183-190.

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans.

Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis.

Kong AM, Pozen A, Anastos K, et al. AIDS Pt Care STDS. 2019;33(3);93-103.

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.

Lee SS, Havens JP, Sayles HR, et al. BMC Infect Dis. 2018;18(1):310.

A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients.

McNicholl IR, Gandhi M, Hare CB, et al. Pharmacotherapy. 2017;37(12):1498-1506.

Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States.

Mizuno Y, Beer L, Huang P, Frazier EL. LGBT Health. 2017;4(3):181-187.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.

Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.

Penn C, Watermeyer J, Evans M. Patient Educ Couns. 2011;83(3):310-318.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients.

Rossetti B, Montagnani F, De Luca A. Expert Opin Pharmacother. 2018;19(7):713-738.

Interdisciplinary care team with pharmacist in a community-based HIV clinic.

Samuel O, Unonu JM, Dotson K, et al. J Natl Med Assoc. 2018;110(4):378-383.

Trends in the San Francisco human immunodeficiency virus epidemic in the "Getting to Zero" era.

Scheer S, Hsu L, Schwarcz S, et al. Clin Infect Dis. 2018;66(7):1027-1034.

Switching antiretroviral regimes for the treatment of HIV: safety implications.

Utrillo L, Vidal F, Puig T, Domingo P. Expert Opin Drug Saf. 2016;15(10):1349-1360.

HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Weidle PJ, Lecher S, Botts LW, et al. J Am Pharm Assoc. 2014; 54(5):486-492.

Part 1: The Pharmacist’s Role in Rapid ART

Supporting Patients With Newly Diagnosed HIV

Part 2: The Pharmacist’s Role in Optimizing HIV Treatment

Supporting the Patients’ Adherence and Retention in Care

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice


Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Answers to Everyday Practice Challenges in HIV Medicine

A Phone-a-Friend CME Series – Volume 2

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice